ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Network pharmacology, bioinformatics analysis, and experimental validation to reveal the target and pharmacological mechanism of DHDK in treating breast cancer.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is the most common cancer among women. Currently, most treatments involve combinations of multiple therapies. However, existing drug therapies remain limited by side effects and drug resistance. (1E,4E)- 1,7-bis(4-hydroxyphenyl)hepta- 1,4-dien- 3-one (DHDK) is a safer, potential targeted drug with strong anti-cancer activity, derived from mistletoe. However, few studies have explored its related treatment mechanisms. This study combined network pharmacology, bioinformatics, molecular docking, and experimental verification to elucidate the mechanism of action of DHDK in treating breast cancer. The SwissTargetPrediction database, Therapeutic Target Databases, and Comparative Toxicogenomics Databases were used for drug target identification. The Gene Expression Omnibus (GEO) database was employed for differential gene screening. The GeneCards, Online Mendelian Inheritance in Man (OMIM) database, and Therapeutic Target Databases (TTD) were utilized to identify DHDK's breast cancer treatment targets. Nexus genes were identified using Cytoscape software after protein-protein interaction (PPI) analysis. Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) Resource were conducted to investigateunderlying mechanisms. Target were identified through molecular docking, and the selected signaling pathway was validatedby qPCR. Comprehensive analysis yielded possible targets and mechanisms: DHDK binds to JAK1, inhibiting the phosphorylation of tyrosine residues in downstream target proteins, recruiting and phosphorylating the transcription factor STAT, downregulating STAT1, and further inhibiting the downstream effector BCL2, ultimately inhibits the anti-apoptotic effect of tumor cells. Therefore, DHDK is a highly promising targeted anti-cancer drug. Clinical trial number: not applicable.
Indexed as
Identifiers
40227311What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.